查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1856204

DNA定序市場：按產品供應、工作流程、技術類型、應用和最終用戶分類－2025-2032年全球預測

DNA Sequencing Market by Offerings, Workflow, Technology Type, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，DNA 定序市場規模將達到 329.5 億美元，複合年成長率為 11.90%。

關鍵市場統計數據
基準年 2024 133.9億美元
預計年份：2025年 149.2億美元
預測年份 2032 329.5億美元
複合年成長率 (%) 11.90%

全面介紹定定序技術進步、監管壓力以及產業相關人員之間的資料工作流程整合的整合背景

引言部分將本執行摘要定位為對DNA定序技術最新發展及其對科研、臨床診斷和產業相關人員的策略影響的關鍵性綜合分析。它闡述了技術創新、法規環境、供應鏈韌性和商業策略之間不斷演變的相互作用，重點強調了化學和儀器技術的漸進式改進如何帶來廣泛的應用和操作複雜性。概述部分闡明了為何需要採用綜合觀點。科技的快速普及、跨行業的應用以及對數據管理日益成長的需求，正在形成一個戰術性和戰略選擇決定競爭優勢的格局。

本文以基礎概念為基礎，概述了塑造該領域的關鍵因素，涵蓋模組化硬體設計、試劑專業化、軟體和分析整合等。文章強調了定序平台與下游生物資訊學的融合，指出從樣本處理到比對、註釋和變異檢測的無縫工作流程已成為獲得可靠結果的先決條件。此外，文章還著重介紹了服務模式的日益普及，例如合約定序和客製化panel設計，這些模式使用戶無需投入大量資金來建立內部平台即可獲得所需的功能。

最後，引言為摘要的其餘部分定下了基調，將技術成熟度與採購、監管合規和人才獲取等方面的實際問題聯繫起來，並強調了採取整體方法的重要性，該方法平衡了眼前的業務重點與對能力、夥伴關係和數據管治的長期投資，以維持科學和商業性目標。

識別正在迅速重塑定序營運模式和競爭格局的技術服務和監管曲折點

DNA定序領域正再形成一系列變革性轉變，這些轉變正共同改變研究機構、臨床實驗室和商業性營業單位的運作方式。定序化學和平台工程的進步提高了定序通量和讀取準確性，同時減少了每個樣本的人工操作時間，從而催生了新的研究設計和診斷流程。同時，第三代定序平台的成熟拓展了長讀長定序的應用範圍，使結構變異檢測和複雜基因組組裝變得更加便利。這些技術進步，以及對最佳化端到端工作流程（包括樣本製備、文庫建構和整合分析）的日益重視，旨在最大限度地減少變異性並加快結果的獲取速度。

同時，經營模式創新正在加速發展。服務供應商正在擴大其合約定定序，並提供模組化分析包，從而能夠外包客製化面板設計和複雜資料解讀等專業任務。這種服務和耗材專業化的趨勢，與儀器設計領域向可擴展、可互通平台發展的平行趨勢相呼應，這些平台可根據通量需求進行客製化。法律規範和支付方的考量也在不斷演變，要求臨床應用必須展現可靠的驗證、可重複性和明確的臨床效用。因此，業內相關人員正在投資於品質系統、標準化通訊協定以及旨在簡化認證流程的夥伴關係。

最後，數據管理和運算能力已成為競爭力的關鍵。為了從日益成長的資料量中提取可操作的洞見，必須改進比對、組裝、註釋和變異檢測演算法。投資於安全、可擴展的數據基礎設施，並配備技術精湛的生物資訊團隊，如今已成為那些致力於將測序結果轉化為轉化研究、定序決策支援和商業性研發成果的機構的戰略重點。

評估2025年貿易措施如何重塑了定序業務的採購架構、供應彈性和供應商夥伴關係。

2025年關稅和貿易措施的實施為定序系統帶來了新的營運考量，影響了籌資策略、供應商關係和成本管理實務。進口關稅的變化影響了資本設備和某些試劑的來源，促使採購負責人分散供應商組合，並重新考慮長期服務契約，以降低政策波動帶來的風險。為此，許多機構優先選擇本地經銷商和區域製造商，以縮短跨境物流的前置作業時間和降低不確定性，同時維持優惠的服務水準安排，確保營運的連續性。

此外，關稅促使買家更加謹慎地進行庫存計劃和合約結構設計，以平衡營運成本限制和安全庫存。合約談判中擴大納入了有關關稅轉嫁、外匯波動和應急供應安排的條款。對於實驗室和服務提供者而言，這導致他們更加重視營運效率，包括流程自動化和試劑節約策略，以抵消進口耗材和設備到岸成本上漲的影響。

關稅環境也加速了國內生產和試劑本地化配製的討論，以減少對單一供應商的依賴。儀器供應商、耗材製造商和本地委託製造製造商正在考慮建立策略聯盟，以建立更具韌性的供應鏈。整體而言，2025年關稅環境的累積影響正促使相關人員採用更靈活的採購框架，投資於供應鏈情報，並尋求結構性調整，以在不斷變化的貿易環境中維持研究的連續性和診斷的可靠性。

明確工作流程技術應用與最終用戶需求的交匯點，以創造差異化價值並確定投資機會的優先順序。

關鍵的細分洞見揭示了在整個定序價值定序中，哪些環節的投資、能力發展和策略差異化最為關鍵。基於產品和服務，市場可細分為耗材和試劑、儀器和平台以及服務。耗材和試劑尤其值得關注的是其技術上的細分，分為酵素和緩衝液以及引子和探針。儀器和平台涵蓋了從DNA定序儀到文庫建構系統和PCR儀等多種類型，工作流程的互通性會影響其應用。服務不僅限於基礎定定序，還包括合約定定序、客製化panel設計以及數據分析和解讀，為透過長期合約和專業知識實現價值獲取提供了途徑。

從工作流程的角度來看，流程分割凸顯了貫穿資料分析、文庫建構、樣本製備和定序本身的端到端流程一致性的重要性。數據分析分為關鍵功能組件，包括比對和組裝、註釋和變異檢測，每個組件都需要有效的演算法和特定領域的專業知識。樣本製備包括DNA萃取和品管，這些步驟直接影響下游讀取品質和結果的可靠性。有效編配這些工作流程步驟可以降低變異性，並提高對研究結果和臨床決策的信心。

次世代定序(NGS) 在高通量應用中佔據主導地位，Sanger 定序仍然是標靶驗證和毛細管檢測的標準方法，而第三代定序(TGS) 則為解析複雜的基因組特徵提供了長讀長應用。應用領域涵蓋農業基因組學、藥物研發、遺傳疾病研究、微生物學（包括微生物組分析和病原體檢測）、腫瘤學（包括癌症基因分型和腫瘤譜分析）、個人化醫療和產前檢測。每種應用都有其獨特的技術、監管和分析要求，從而影響採購和夥伴關係的選擇。最終用戶包括學術和研究機構（例如政府研究機構和大學實驗室）、受託研究機構、醫院、診斷實驗室以及製藥和生物技術公司。每個最終用戶都有其自身的處理能力、品質標準和服務偏好，這些都會影響供應商的打入市場策略。

影響全球各地區策略市場策略的監管環境，以及影響各地區供應鏈優先事項的採用促進因素

來自各個地區的洞察揭示了企業在定位其定序資產和規劃市場進入方式上的不同策略重點和營運環境。在美洲，強大的研究資助體系和成熟的臨床基因組學計畫支撐了對先進平台、全面的試劑組合和整合檢測的高需求。這種環境有利於那些能夠提供檢驗的臨床工作流程、強大的售後支援以及加速轉化研究的合作研究夥伴關係的供應商和服務供應商。雖然跨境供應鏈仍然重要，但擴大關鍵耗材的國內生產能力以增強韌性也備受關注。

在歐洲、中東和非洲，統一的監管環境和分散的報銷體系促使企業採取謹慎而審慎的實施路徑，優先考慮臨床效用和符合當地認證要求。能夠提供完善的品管系統、在地化支援和在地化驗證方案的供應商正贏得客戶的青睞。同時，在亞太地區，我們看到能力和規模的多樣性：成熟市場正在快速採用高通量NGS和新興的長讀長定序技術，而發展中市場則優先考慮可擴展、經濟高效的平台和耗材，以支持公共衛生和農業基因組學計畫。在所有地區，本地夥伴關係、人才培養和植根於當地的服務舉措對於持續合作和商業性成功至關重要。

分析策略夥伴關係和專業服務模式如何影響定序的競爭差異化和下游應用。

本報告重點闡述了主要企業和新興企業如何圍繞核心競爭力、夥伴關係模式和服務組合進行市場定位，從而在整個定序生態系統中獲取價值。一些公司正大力投資於平台性能和化學創新，以確保技術差異化；而另一些公司則在拓展耗材產品組合和服務能力，以創造持續的收入來源。儀器製造商和試劑供應商之間的策略聯盟日益普遍，使他們能夠提供捆綁式產品，從而簡化採購流程並加快終端用戶的檢驗速度。同時，越來越多的服務供應商和專業分析公司正透過先進的生物資訊學、法規支援以及面向臨床的複雜應用場景工作流程來實現差異化競爭優勢。

併購和授權協議仍是彌補能力缺口、開拓新區域市場以及整合專有檢測方法和計算流程的重要手段。需要快速部署、認證支援和全生命週期維護的臨床和診斷實驗室更青睞擁有強大銷售管道和本地化技術支援的行業參與者。新參與企業通常在長讀長結構變異分析和高通量多重檢測等細分應用領域競爭，並強調與臨床和研究機構建立合作關係以檢驗應用案例。在整個競爭格局中，產品開發的敏捷性、強大的售後支援以及清晰的監管和品質文件正成為影響採購決策和長期客戶關係的關鍵差異化因素。

為技術開發人員、服務供應商和負責人提供切實可行的策略指導，以使其產品模組化、監管合規性和供應鏈彈性與成長目標保持一致。

針對產業領導者的實際建議著重於協調技術開發、商業策略和營運韌性，以實現永續優勢。領導者應優先考慮模組化平台設計和開放式儀器生態系統，以促進第三方耗材的整合，並降低客戶的整體擁有成本。投資於試劑可靠性和​​標準化文庫製備試劑套件，並輔以清晰的驗證方案，將減少臨床和高通量研究使用者實施過程中的阻力。同時，將涵蓋比對、組裝、註釋和變異檢測等強大的分析功能整合到產品套件和服務中，將增強產品的感知價值提案，並使客戶能夠更快地獲得可操作的洞察。

在供應和採購方面，企業必須實現採購管道多元化，並考慮建立區域製造夥伴關係，以降低貿易和關稅風險。透過合約排序、客製化樣本設計和資料解讀管理服務，建立以服務為中心的收入來源，可以平穩收入波動並加深客戶關係。積極主動地為客戶提供驗證包、合規文件和上市後監測證​​據，可以加速臨床應用並減少報銷障礙。最後，結合培訓計畫、技術支援和合作研究舉措的人才策略，可以幫助企業在不降低品質的前提下，維持高標準的服務並擴大營運規模。

透明的多來源調查方法，結合相關人員訪談、文獻綜述和工作流程分析，檢驗了業界考察和結論。

本執行摘要的調查方法融合了多種定性和定量方法，以確保研究結果的穩健性和可重複性。主要研究包括對行業高管、實驗室主任和採購專業人員進行結構化訪談，以獲取關於技術採納、檢驗要求和供應鏈動態的第一手觀點。次要研究整合了同行評審文獻、監管指導文件、技術白皮書和公司披露資訊，以檢驗更廣泛的科學和商業性環境中的趨勢，並整理訪談內容。透過對這些資訊來源進行三角驗證，最大限度地減少偏差，並為主題結論提供支持。

此分析架構著重於價值鏈分解、工作流程映射和能力差距分析，以識別摩擦和機會並存之處。細分分析旨在反映真實的採購和業務行為，將產品、工作流程、技術類型、應用和最終用戶與部署和規模化的實際考慮相匹配。品管包括使用獨立實驗室報告交叉檢驗技術聲明，並透過與多家經銷商訪談來確認供應鏈聲明。調查方法強調假設的透明度、可複現的文獻綜述搜尋策略以及清晰的訪談通訊協定，以便為未來的更新和客製化研究擴展提供支持。

本文簡要總結了技術法規和商業性趨勢對建構韌性能力和競爭優勢定位的影響，並確定了優先事項。

結論綜合分析了技術進步、監管演變、地理差異以及商業策略等核心因素對定序領域相關人員的影響。化學和平台設計的技術改進拓展了可行應用範圍，而服務和耗材的專業化則提供了靈活的實施路徑，無需大量資本投資。監管和貿易的變化凸顯了營運適應性的必要性，尤其是在採購和供應鏈規劃方面，以及與認證和報銷相關人員的積極互動。綜上所述，這些動態有利於那些能夠將可靠的儀器、檢驗的耗材、整合的分析系統和響應迅速的支援網路相結合的機構。

未來的成功取決於如何在確保供應鏈韌性和分析結果可重複性等緊迫業務需求與持續投資於平台差異化和員工能力建設之間取得平衡。積極尋求策略夥伴關係、在必要時實現關鍵供應能力的在地化，並提供清晰的檢驗方案的機構，更有可能降低臨床和研究領域的應用門檻。同樣重要的是，投資於安全、可擴展的數據基礎設施和先進的生物資訊技術，將原始定序結果轉化為具有臨床意義且科學嚴謹的洞見。這種整合式方法將使相關人員能夠在應對快速變化的技術和法規環境所帶來的複雜性的同時，掌握不斷湧現的機會。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 引入即時奈米孔定序，用於攜帶式現場診斷和流行病學研究
  • 單細胞多組體學整合技術的進步使得高解析度細胞分析成為可能。
  • ctDNA液態切片檢測在癌症早期檢測和監測的臨床應用
  • 開發長讀長定序平台以提高複雜基因組中結構變異的檢測能力
  • 擴展基於 CRISPR 的定序方法以進行標靶序列捕獲和甲基化分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. DNA定序市場依產品/服務分類

  • 耗材和試劑
    • 酵素和緩衝液
    • 引子和探針
  • 設備與平台
    • DNA定序儀
    • 圖書館製備系統
    • PCR裝置
  • 服務
    • 定序合約
    • 客製化面板設計
    • 數據分析與解讀

9. 按工作流程分類的DNA定序市場

  • 數據分析
    • 校準與裝配
    • 註解
    • 變異調用
  • 圖書館準備
  • 樣品製備
    • DNA萃取
    • 品管
  • 順序

第10章：依技術類型分類的DNA定序市場

  • 下一代定序（NGS）
  • 桑格定序
  • 第三代定序（TGS）

第11章 DNA定序市場依應用領域分類

  • 農業基因組學
  • 藥物發現
  • 遺傳疾病研究
  • 微生物學
    • 微生物組分析
    • 病原體檢測
  • 腫瘤學
    • 癌症基因基因型鑒定
    • 腫瘤譜分析
  • 個人化醫療
  • 產前檢查

第12章 DNA定序市場（依最終用戶分類）

  • 學術和研究機構
    • 政府研究所
    • 大學研究機構
  • 受託研究機構
  • 醫院和診斷實驗室
  • 製藥和生物技術公司

13. 按地區分類的DNA定序市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 DNA定序市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國DNA定序市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Agilent Technologies, Inc.
    • Becton, Dickinson and Company
    • BGI Genomics Co., Ltd.
    • Bio-Rad Laboratories, Inc.
    • Eurofins Scientific SE
    • F. Hoffmann-La Roche Ltd.
    • Laboratory Corporation of America Holdings
    • Azenta, Inc.
    • Illumina, Inc.
    • Macrogen Inc.
    • Oxford Nanopore Technologies PLC
    • PerkinElmer, Inc.
    • QIAGEN NV
    • Myriad Genetics, Inc.
    • Thermo Fisher Scientific Inc.
    • Twist Bioscience Corporation
    • Abbott Laboratories
    • Danaher Corporation
    • Merck KGaA
    • Pacific Biosciences of California, Inc.
    • Novogene Co, Ltd.
    • Shimadzu Corporation
    • Genomics England
    • Eppendorf SE
    • 10x Genomics, Inc.
    • BioChain Institute Inc.
    • Genscript Biotech Corporation
    • Sartorius AG
    • Charles River Laboratories International, Inc.
    • Johnson & Johnson Services, Inc.
    • AbbVie Inc.
    • Partek Inc.
    • Novartis AG
Product Code: MRR-450A0628CCF5

The DNA Sequencing Market is projected to grow by USD 32.95 billion at a CAGR of 11.90% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 13.39 billion
Estimated Year [2025] USD 14.92 billion
Forecast Year [2032] USD 32.95 billion
CAGR (%) 11.90%

Comprehensive opening context framing the convergence of sequencing technology advances regulatory pressures and data workflow integration across industry stakeholders

The introduction positions this executive summary as an essential synthesis of contemporary developments in DNA sequencing technologies and their strategic implications for stakeholders across research, clinical diagnostics, and industry. It frames the evolving interplay between technical innovation, regulatory environments, supply chain resiliency, and commercial strategy, emphasizing how incremental improvements in chemistry and instrumentation are translating into broader application scope and operational complexity. This overview clarifies why a consolidated perspective is necessary: rapid technology diffusion, cross-sector adoption, and heightened data management demands create a landscape where tactical and strategic choices determine competitive advantage.

Building on foundational concepts, the introduction outlines the principal vectors shaping the sector, from modular hardware design and reagent specialization to software and analytics integration. It highlights the convergence between sequencing platforms and downstream bioinformatics, where seamless workflows from sample handling through alignment, annotation, and variant calling are becoming a prerequisite for reliable outputs. The narrative also signals growing emphasis on service models, including contract sequencing and custom panel design, which allow organizations to access capabilities without the full capital outlay associated with in-house platforms.

Finally, the introduction establishes the tone for the remainder of the summary by linking technological maturation with pragmatic concerns for procurement, regulatory adherence, and talent acquisition. It underscores the importance of adopting a holistic approach that balances immediate operational priorities with longer-term investments in capabilities, partnerships, and data governance that will sustain scientific and commercial objectives.

Identifying the technological service and regulatory inflection points that are rapidly redefining operational models and competitive dynamics in sequencing

The landscape of DNA sequencing is being reshaped by a set of transformative shifts that collectively alter how research institutions, clinical laboratories, and commercial entities operate. Advances in sequencing chemistry and platform engineering are increasing throughput and read accuracy while reducing per-sample hands-on time, which in turn enables new study designs and diagnostic workflows. At the same time, the maturation of third-generation platforms has expanded capability envelopes for long-read applications, making structural variant detection and complex genome assembly more accessible. These technological gains are complemented by greater emphasis on end-to-end workflow optimization, where sample preparation, library construction, and integrated analytics are designed to minimize variability and accelerate time to result.

Concurrently, business model innovation is accelerating. Service providers are scaling contract sequencing and offering modular analytics packages that allow clients to outsource specialized tasks such as custom panel design or complex data interpretation. This shift toward services and consumable specialization is supported by a parallel trend in instrument design toward scalable, interoperable platforms that can be tailored to throughput needs. Regulatory frameworks and payer considerations are also evolving, pushing clinical applications to demonstrate robust validation, reproducibility, and clear clinical utility. As a result, industry players are investing in quality systems, standardized protocols, and partnerships that streamline certification pathways.

Finally, data stewardship and computational capacity have become central to competitiveness. Enhanced algorithms for alignment, assembly, annotation, and variant calling are necessary to extract actionable insights from growing data volumes. Investment in secure, scalable data infrastructure, combined with skilled bioinformatics teams, is now a strategic priority for organizations aiming to translate sequencing outputs into translational research, diagnostic decision support, or commercial R&D outcomes.

Assessing how 2025 trade measures have reshaped procurement architectures supply resilience and supplier partnerships across sequencing operations

The introduction of tariffs and trade measures in 2025 has introduced new operational considerations throughout the sequencing ecosystem, affecting procurement strategies, supplier relationships, and cost management practices. Changes to import duties have influenced where capital equipment and certain reagents are sourced, prompting procurement leads to diversify supplier portfolios and to reexamine long-term service agreements to mitigate exposure to policy volatility. In response, many organizations have prioritized local distributors and regional manufacturers to reduce lead times and uncertainty associated with cross-border logistics, while maintaining preferential service-level arrangements to preserve continuity of operations.

Moreover, tariffs have led to more deliberate inventory planning and contract structuring, as purchasers balance safety stock against working capital constraints. Contract negotiations increasingly include clauses that address tariff pass-through, currency fluctuations, and contingency supply arrangements. For laboratories and service providers, the consequence has been a renewed focus on operational efficiency, including process automation and reagent conservation strategies, to offset the impact of higher landed costs for certain imported consumables and instruments.

The tariff environment has also accelerated discussions around in-country manufacturing and localized reagent formulation to reduce dependence on single points of supply. Strategic partnerships between instrument vendors, consumable manufacturers, and local contract manufacturers are being explored to create more resilient supply networks. Overall, the cumulative impact of the 2025 tariff landscape is prompting stakeholders to adopt more flexible procurement frameworks, invest in supply chain intelligence, and pursue structural adjustments that preserve research continuity and diagnostic reliability in a shifting trade environment.

Uncovering where offerings workflow technology applications and end-user needs converge to create differentiated value and targeted investment priorities

Key segmentation insights illuminate where investment, capability development, and strategic differentiation are most consequential across the sequencing value chain. Based on product and service offerings, the market differentiates between consumables and reagents, instruments and platforms, and services. Consumables and reagents merits particular attention with its technical bifurcation into enzymes and buffers versus primers and probes, both of which drive assay performance and reproducibility. Instruments and platforms span DNA sequencers, library preparation systems, and PCR machines, and their interoperability with workflows influences adoption. Services extend beyond basic sequencing to encompass contract sequencing, custom panel design, and data analysis and interpretation, offering routes to capture value through recurring engagements and specialized expertise.

When examined through the workflow lens, segmentation highlights the importance of end-to-end process coherence across data analysis, library preparation, sample preparation, and sequencing itself. Data analysis divides into critical functional components such as alignment and assembly, annotation, and variant calling, each requiring validated algorithms and domain-specific expertise. Sample preparation includes DNA extraction and quality control, stages that directly affect downstream read quality and result reliability. Effective orchestration across these workflow stages reduces variability and enhances confidence in both research outcomes and clinical decisions.

Technology type remains a principal axis of differentiation, with Next-Generation Sequencing (NGS) dominating high-throughput applications, Sanger sequencing remaining a staple for targeted validation and capillary-based assays, and Third-Generation Sequencing (TGS) enabling long-read applications that resolve complex genomic features. Application segmentation spans agricultural genomics, drug discovery, genetic disease research, microbiology-which itself includes microbiome analysis and pathogen detection-oncology with cancer genotyping and tumor profiling, personalized medicine, and prenatal testing. Each application imposes distinct technical, regulatory, and analytical requirements, shaping procurement and partnership choices. Finally, end users range from academic and research institutions, which include government research institutes and university labs, to contract research organizations, hospitals and diagnostic laboratories, and pharmaceutical and biotechnology companies; each end-user category has unique throughput expectations, quality standards, and service preferences, informing vendor go-to-market strategies.

Differentiating regional adoption drivers regulatory conditions and supply chain priorities that determine strategic market approaches across global geographies

Regional insights reveal divergent strategic priorities and operational conditions that inform how organizations deploy sequencing assets and plan market entry. In the Americas, strong research funding ecosystems and established clinical genomics programs support high demand for advanced platforms, comprehensive reagent portfolios, and integrated analytics. This environment favors vendors and service providers that can deliver validated clinical workflows, strong post-sale support, and collaborative research partnerships that accelerate translational pipelines. Cross-border supply chains remain important, but there is also a pronounced interest in capacity expansion for domestic production of critical consumables to strengthen resilience.

Across Europe, the Middle East & Africa, regulatory harmonization and fragmented reimbursement landscapes drive a cautious but methodical adoption path, where demonstrable clinical utility and compliance with regional certification are paramount. Vendors that offer robust quality management systems, localized support, and regionally adapted validation packages find receptive customers. In contrast, the Asia-Pacific region exhibits heterogeneity in capability and scale, with mature markets rapidly deploying both high-throughput NGS and emerging long-read technologies, while developing markets prioritize scalable, cost-efficient platforms and consumables that can support public health and agricultural genomics initiatives. Across all regions, regional partnerships, talent development, and localized service models are central to sustained engagement and commercial success.

Analyzing how corporate strategies partnerships and specialized service models are shaping competitive differentiation and downstream adoption in sequencing

Key company insights focus on how leading and emerging players are positioning around core competencies, partnership models, and service portfolios to capture value across the sequencing ecosystem. Some organizations are concentrating investment on platform performance and chemistry innovation to secure technological differentiation, while others are expanding their consumable portfolios and service capabilities to generate recurring revenue streams. Strategic alliances between instrument manufacturers and reagent suppliers are becoming more common, enabling bundled offerings that simplify procurement and shorten validation timelines for end users. Simultaneously, a cohort of service providers and specialized analytics companies are distinguishing themselves through advanced bioinformatics, regulatory support, and clinically oriented workflows that address high-complexity use cases.

Mergers, acquisitions, and licensing agreements remain instrumental tools for filling capability gaps, accessing new regional markets, and integrating proprietary assays or computational pipelines. Industrial players with robust distribution channels and localized technical support are favored by clinical and diagnostic laboratories that require rapid installation, certification support, and lifecycle maintenance. New entrants often compete on niche applications, such as long-read structural variant analysis or highly multiplexed panel assays, leveraging focused clinical or research partnerships to validate use cases. Across the competitive landscape, agility in product development, depth of post-market support, and clarity of regulatory and quality documentation are recurring differentiators that influence procurement decisions and long-term customer relationships.

Practical strategic guidance for technology developers service providers and purchasers to align product modularity regulatory preparedness and supply resilience with growth objectives

Actionable recommendations for industry leaders emphasize aligning technology development, commercial strategy, and operational resilience to realize sustainable advantage. Leaders should prioritize modular platform designs and open instrument ecosystems that facilitate third-party consumable integration and reduce total cost of ownership for customers. Investing in reagent reliability and standardized library preparation kits, coupled with clear validation protocols, will decrease onboarding friction for clinical and high-throughput research users. Simultaneously, embedding robust analytics capabilities-covering alignment, assembly, annotation, and variant calling-into product suites or service offerings will enhance the perceived value proposition and enable customers to derive actionable insights more rapidly.

On the procurement and supply side, firms must diversify sourcing and consider regional manufacturing partnerships to mitigate trade and tariff risks. Building service-centric revenue streams through contract sequencing, tailored panel design, and managed data interpretation services can smooth revenue volatility and foster deeper client relationships. Regulatory engagement is also critical: proactively supporting customers with validation packages, compliance documentation, and post-market surveillance evidence will accelerate clinical adoption and reduce barriers to reimbursement. Finally, workforce strategies that combine training programs, embedded technical support, and collaborative research initiatives will help organizations maintain high service standards and scale operations without compromising quality.

Transparent multi-source research methodology combining stakeholder interviews literature synthesis and workflow analysis to validate industry insights and conclusions

The research methodology underpinning this executive summary integrates multiple qualitative and quantitative approaches to ensure robust, reproducible findings. Primary research included structured interviews with industry executives, laboratory directors, and procurement specialists to capture firsthand perspectives on technology adoption, validation requirements, and supply chain dynamics. Secondary research synthesized peer-reviewed literature, regulatory guidance documents, technical white papers, and company disclosures to validate trends and contextualize interview insights within the broader scientific and commercial environment. Triangulation across these sources was applied to minimize bias and to corroborate thematic conclusions.

Analytical frameworks focused on value-chain decomposition, workflow mapping, and capability gap analysis to identify where friction and opportunity coexist. Segmentation analyses were constructed to reflect real-world purchasing and operational behaviors, aligning offerings, workflows, technology types, applications, and end users to practical considerations for deployment and scale. Quality control measures included cross-validation of technical claims with independent laboratory reports and confirmation of supply chain assertions through multiple distributor interviews. The methodology privileges transparency in assumptions, replicable search strategies for literature synthesis, and clear documentation of interview protocols to support future updates and bespoke research extensions.

Concise synthesis of implications from technological regulatory and commercial trends that define priorities for resilient capability building and competitive positioning

The conclusion synthesizes the core implications of technological advancement, regulatory evolution, regional divergence, and commercial strategy for stakeholders operating in the sequencing domain. Technological improvements in chemistry and platform design are expanding the range of feasible applications, while services and consumable specialization provide flexible pathways for adoption without extensive capital investment. Regulatory and trade shifts underscore the need for operational adaptability, particularly in procurement and supply chain planning, and for proactive engagement with certification and reimbursement stakeholders. Collectively, these dynamics favor organizations that can combine reliable instrumentation, validated consumables, integrated analytics, and responsive support networks.

Going forward, success will hinge on balancing immediate operational imperatives-such as securing resilient supply chains and ensuring analytical reproducibility-with sustained investments in platform differentiation and workforce capabilities. Organizations that pursue strategic partnerships, localize critical supply functions where appropriate, and deliver clear validation packages will lower barriers to adoption in clinical and research settings. Equally important are investments in secure, scalable data infrastructure and advanced bioinformatics to convert raw sequencing outputs into clinically meaningful and scientifically rigorous insights. This integrated approach positions stakeholders to capitalize on evolving opportunities while managing the complexities inherent in a fast-moving technological and regulatory environment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Implementation of real-time nanopore sequencing for portable field diagnostics and epidemiology
  • 5.2. Advancements in single-cell multi-omics integration enabling high-resolution cellular profiling
  • 5.3. Clinical adoption of liquid biopsy assays leveraging ctDNA for early cancer detection and monitoring
  • 5.4. Development of long-read sequencing platforms improving structural variant detection in complex genomes
  • 5.5. Expansion of CRISPR-based sequencing methods for targeted enrichment and methylation analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. DNA Sequencing Market, by Offerings

  • 8.1. Consumables & Reagents
    • 8.1.1. Enzymes & Buffers
    • 8.1.2. Primers & Probes
  • 8.2. Instruments & Platforms
    • 8.2.1. DNA Sequencers
    • 8.2.2. Library Preparation Systems
    • 8.2.3. PCR Machines
  • 8.3. Services
    • 8.3.1. Contract Sequencing
    • 8.3.2. Custom Panel Design
    • 8.3.3. Data Analysis & Interpretation

9. DNA Sequencing Market, by Workflow

  • 9.1. Data Analysis
    • 9.1.1. Alignment & Assembly
    • 9.1.2. Annotation
    • 9.1.3. Variant Calling
  • 9.2. Library Preparation
  • 9.3. Sample Preparation
    • 9.3.1. DNA Extraction
    • 9.3.2. Quality Control
  • 9.4. Sequencing

10. DNA Sequencing Market, by Technology Type

  • 10.1. Next-Generation Sequencing (NGS)
  • 10.2. Sanger Sequencing
  • 10.3. Third-Generation Sequencing (TGS)

11. DNA Sequencing Market, by Application

  • 11.1. Agricultural Genomics
  • 11.2. Drug Discovery
  • 11.3. Genetic Disease Research
  • 11.4. Microbiology
    • 11.4.1. Microbiome Analysis
    • 11.4.2. Pathogen Detection
  • 11.5. Oncology
    • 11.5.1. Cancer Genotyping
    • 11.5.2. Tumor Profiling
  • 11.6. Personalized Medicine
  • 11.7. Prenatal Testing

12. DNA Sequencing Market, by End User

  • 12.1. Academic & Research Institutions
    • 12.1.1. Government Research Institutes
    • 12.1.2. University Labs
  • 12.2. Contract Research Organizations
  • 12.3. Hospitals & Diagnostic Laboratories
  • 12.4. Pharmaceutical & Biotechnology Companies

13. DNA Sequencing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. DNA Sequencing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. DNA Sequencing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Agilent Technologies, Inc.
    • 16.3.2. Becton, Dickinson and Company
    • 16.3.3. BGI Genomics Co., Ltd.
    • 16.3.4. Bio-Rad Laboratories, Inc.
    • 16.3.5. Eurofins Scientific SE
    • 16.3.6. F. Hoffmann-La Roche Ltd.
    • 16.3.7. Laboratory Corporation of America Holdings
    • 16.3.8. Azenta, Inc.
    • 16.3.9. Illumina, Inc.
    • 16.3.10. Macrogen Inc.
    • 16.3.11. Oxford Nanopore Technologies PLC
    • 16.3.12. PerkinElmer, Inc.
    • 16.3.13. QIAGEN N.V.
    • 16.3.14. Myriad Genetics, Inc.
    • 16.3.15. Thermo Fisher Scientific Inc.
    • 16.3.16. Twist Bioscience Corporation
    • 16.3.17. Abbott Laboratories
    • 16.3.18. Danaher Corporation
    • 16.3.19. Merck KGaA
    • 16.3.20. Pacific Biosciences of California, Inc.
    • 16.3.21. Novogene Co, Ltd.
    • 16.3.22. Shimadzu Corporation
    • 16.3.23. Genomics England
    • 16.3.24. Eppendorf SE
    • 16.3.25. 10x Genomics, Inc.
    • 16.3.26. BioChain Institute Inc.
    • 16.3.27. Genscript Biotech Corporation
    • 16.3.28. Sartorius AG
    • 16.3.29. Charles River Laboratories International, Inc.
    • 16.3.30. Johnson & Johnson Services, Inc.
    • 16.3.31. AbbVie Inc.
    • 16.3.32. Partek Inc.
    • 16.3.33. Novartis AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL DNA SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DNA SEQUENCING MARKET SIZE, BY OFFERINGS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL DNA SEQUENCING MARKET SIZE, BY OFFERINGS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL DNA SEQUENCING MARKET SIZE, BY WORKFLOW, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL DNA SEQUENCING MARKET SIZE, BY WORKFLOW, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DNA SEQUENCING MARKET SIZE, BY TECHNOLOGY TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL DNA SEQUENCING MARKET SIZE, BY TECHNOLOGY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DNA SEQUENCING MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL DNA SEQUENCING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DNA SEQUENCING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL DNA SEQUENCING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DNA SEQUENCING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS DNA SEQUENCING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA DNA SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA DNA SEQUENCING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE DNA SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST DNA SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA DNA SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC DNA SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL DNA SEQUENCING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN DNA SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC DNA SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION DNA SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS DNA SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 DNA SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO DNA SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL DNA SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. DNA SEQUENCING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. DNA SEQUENCING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. DNA SEQUENCING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL DNA SEQUENCING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL DNA SEQUENCING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL DNA SEQUENCING MARKET SIZE, BY OFFERINGS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL DNA SEQUENCING MARKET SIZE, BY OFFERINGS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL DNA SEQUENCING MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL DNA SEQUENCING MARKET SIZE, BY CONSUMABLES & REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL DNA SEQUENCING MARKET SIZE, BY CONSUMABLES & REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL DNA SEQUENCING MARKET SIZE, BY CONSUMABLES & REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL DNA SEQUENCING MARKET SIZE, BY CONSUMABLES & REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL DNA SEQUENCING MARKET SIZE, BY CONSUMABLES & REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL DNA SEQUENCING MARKET SIZE, BY CONSUMABLES & REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL DNA SEQUENCING MARKET SIZE, BY CONSUMABLES & REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL DNA SEQUENCING MARKET SIZE, BY ENZYMES & BUFFERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL DNA SEQUENCING MARKET SIZE, BY ENZYMES & BUFFERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL DNA SEQUENCING MARKET SIZE, BY ENZYMES & BUFFERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL DNA SEQUENCING MARKET SIZE, BY ENZYMES & BUFFERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL DNA SEQUENCING MARKET SIZE, BY ENZYMES & BUFFERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL DNA SEQUENCING MARKET SIZE, BY ENZYMES & BUFFERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL DNA SEQUENCING MARKET SIZE, BY PRIMERS & PROBES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL DNA SEQUENCING MARKET SIZE, BY PRIMERS & PROBES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL DNA SEQUENCING MARKET SIZE, BY PRIMERS & PROBES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL DNA SEQUENCING MARKET SIZE, BY PRIMERS & PROBES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL DNA SEQUENCING MARKET SIZE, BY PRIMERS & PROBES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL DNA SEQUENCING MARKET SIZE, BY PRIMERS & PROBES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL DNA SEQUENCING MARKET SIZE, BY INSTRUMENTS & PLATFORMS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL DNA SEQUENCING MARKET SIZE, BY INSTRUMENTS & PLATFORMS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL DNA SEQUENCING MARKET SIZE, BY INSTRUMENTS & PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL DNA SEQUENCING MARKET SIZE, BY INSTRUMENTS & PLATFORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL DNA SEQUENCING MARKET SIZE, BY INSTRUMENTS & PLATFORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL DNA SEQUENCING MARKET SIZE, BY INSTRUMENTS & PLATFORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL DNA SEQUENCING MARKET SIZE, BY INSTRUMENTS & PLATFORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL DNA SEQUENCING MARKET SIZE, BY INSTRUMENTS & PLATFORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL DNA SEQUENCING MARKET SIZE, BY DNA SEQUENCERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL DNA SEQUENCING MARKET SIZE, BY DNA SEQUENCERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL DNA SEQUENCING MARKET SIZE, BY DNA SEQUENCERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL DNA SEQUENCING MARKET SIZE, BY DNA SEQUENCERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL DNA SEQUENCING MARKET SIZE, BY DNA SEQUENCERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL DNA SEQUENCING MARKET SIZE, BY DNA SEQUENCERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL DNA SEQUENCING MARKET SIZE, BY LIBRARY PREPARATION SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL DNA SEQUENCING MARKET SIZE, BY LIBRARY PREPARATION SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL DNA SEQUENCING MARKET SIZE, BY LIBRARY PREPARATION SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL DNA SEQUENCING MARKET SIZE, BY LIBRARY PREPARATION SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL DNA SEQUENCING MARKET SIZE, BY LIBRARY PREPARATION SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL DNA SEQUENCING MARKET SIZE, BY LIBRARY PREPARATION SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL DNA SEQUENCING MARKET SIZE, BY PCR MACHINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL DNA SEQUENCING MARKET SIZE, BY PCR MACHINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL DNA SEQUENCING MARKET SIZE, BY PCR MACHINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL DNA SEQUENCING MARKET SIZE, BY PCR MACHINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL DNA SEQUENCING MARKET SIZE, BY PCR MACHINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL DNA SEQUENCING MARKET SIZE, BY PCR MACHINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL DNA SEQUENCING MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL DNA SEQUENCING MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL DNA SEQUENCING MARKET SIZE, BY SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL DNA SEQUENCING MARKET SIZE, BY SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL DNA SEQUENCING MARKET SIZE, BY SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL DNA SEQUENCING MARKET SIZE, BY SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL DNA SEQUENCING MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL DNA SEQUENCING MARKET SIZE, BY SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL DNA SEQUENCING MARKET SIZE, BY CONTRACT SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL DNA SEQUENCING MARKET SIZE, BY CONTRACT SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL DNA SEQUENCING MARKET SIZE, BY CONTRACT SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL DNA SEQUENCING MARKET SIZE, BY CONTRACT SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL DNA SEQUENCING MARKET SIZE, BY CONTRACT SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL DNA SEQUENCING MARKET SIZE, BY CONTRACT SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL DNA SEQUENCING MARKET SIZE, BY CUSTOM PANEL DESIGN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL DNA SEQUENCING MARKET SIZE, BY CUSTOM PANEL DESIGN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL DNA SEQUENCING MARKET SIZE, BY CUSTOM PANEL DESIGN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL DNA SEQUENCING MARKET SIZE, BY CUSTOM PANEL DESIGN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL DNA SEQUENCING MARKET SIZE, BY CUSTOM PANEL DESIGN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL DNA SEQUENCING MARKET SIZE, BY CUSTOM PANEL DESIGN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL DNA SEQUENCING MARKET SIZE, BY DATA ANALYSIS & INTERPRETATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL DNA SEQUENCING MARKET SIZE, BY DATA ANALYSIS & INTERPRETATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL DNA SEQUENCING MARKET SIZE, BY DATA ANALYSIS & INTERPRETATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL DNA SEQUENCING MARKET SIZE, BY DATA ANALYSIS & INTERPRETATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL DNA SEQUENCING MARKET SIZE, BY DATA ANALYSIS & INTERPRETATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL DNA SEQUENCING MARKET SIZE, BY DATA ANALYSIS & INTERPRETATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL DNA SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL DNA SEQUENCING MARKET SIZE, BY WORKFLOW, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL DNA SEQUENCING MARKET SIZE, BY DATA ANALYSIS, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL DNA SEQUENCING MARKET SIZE, BY DATA ANALYSIS, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL DNA SEQUENCING MARKET SIZE, BY DATA ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL DNA SEQUENCING MARKET SIZE, BY DATA ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL DNA SEQUENCING MARKET SIZE, BY DATA ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL DNA SEQUENCING MARKET SIZE, BY DATA ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL DNA SEQUENCING MARKET SIZE, BY DATA ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL DNA SEQUENCING MARKET SIZE, BY DATA ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL DNA SEQUENCING MARKET SIZE, BY ALIGNMENT & ASSEMBLY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL DNA SEQUENCING MARKET SIZE, BY ALIGNMENT & ASSEMBLY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL DNA SEQUENCING MARKET SIZE, BY ALIGNMENT & ASSEMBLY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL DNA SEQUENCING MARKET SIZE, BY ALIGNMENT & ASSEMBLY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL DNA SEQUENCING MARKET SIZE, BY ALIGNMENT & ASSEMBLY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL DNA SEQUENCING MARKET SIZE, BY ALIGNMENT & ASSEMBLY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL DNA SEQUENCING MARKET SIZE, BY ANNOTATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL DNA SEQUENCING MARKET SIZE, BY ANNOTATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL DNA SEQUENCING MARKET SIZE, BY ANNOTATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL DNA SEQUENCING MARKET SIZE, BY ANNOTATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL DNA SEQUENCING MARKET SIZE, BY ANNOTATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL DNA SEQUENCING MARKET SIZE, BY ANNOTATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL DNA SEQUENCING MARKET SIZE, BY VARIANT CALLING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL DNA SEQUENCING MARKET SIZE, BY VARIANT CALLING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL DNA SEQUENCING MARKET SIZE, BY VARIANT CALLING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL DNA SEQUENCING MARKET SIZE, BY VARIANT CALLING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL DNA SEQUENCING MARKET SIZE, BY VARIANT CALLING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL DNA SEQUENCING MARKET SIZE, BY VARIANT CALLING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL DNA SEQUENCING MARKET SIZE, BY LIBRARY PREPARATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL DNA SEQUENCING MARKET SIZE, BY LIBRARY PREPARATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL DNA SEQUENCING MARKET SIZE, BY LIBRARY PREPARATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL DNA SEQUENCING MARKET SIZE, BY LIBRARY PREPARATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL DNA SEQUENCING MARKET SIZE, BY LIBRARY PREPARATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL DNA SEQUENCING MARKET SIZE, BY LIBRARY PREPARATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL DNA SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL DNA SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL DNA SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL DNA SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL DNA SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL DNA SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL DNA SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL DNA SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL DNA SEQUENCING MARKET SIZE, BY DNA EXTRACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL DNA SEQUENCING MARKET SIZE, BY DNA EXTRACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL DNA SEQUENCING MARKET SIZE, BY DNA EXTRACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL DNA SEQUENCING MARKET SIZE, BY DNA EXTRACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL DNA SEQUENCING MARKET SIZE, BY DNA EXTRACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL DNA SEQUENCING MARKET SIZE, BY DNA EXTRACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL DNA SEQUENCING MARKET SIZE, BY QUALITY CONTROL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL DNA SEQUENCING MARKET SIZE, BY QUALITY CONTROL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL DNA SEQUENCING MARKET SIZE, BY QUALITY CONTROL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL DNA SEQUENCING MARKET SIZE, BY QUALITY CONTROL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL DNA SEQUENCING MARKET SIZE, BY QUALITY CONTROL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL DNA SEQUENCING MARKET SIZE, BY QUALITY CONTROL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL DNA SEQUENCING MARKET SIZE, BY SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL DNA SEQUENCING MARKET SIZE, BY SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL DNA SEQUENCING MARKET SIZE, BY SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL DNA SEQUENCING MARKET SIZE, BY SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL DNA SEQUENCING MARKET SIZE, BY SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL DNA SEQUENCING MARKET SIZE, BY SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL DNA SEQUENCING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL DNA SEQUENCING MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL DNA SEQUENCING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL DNA SEQUENCING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL DNA SEQUENCING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL DNA SEQUENCING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL DNA SEQUENCING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL DNA SEQUENCING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL DNA SEQUENCING MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL DNA SEQUENCING MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL DNA SEQUENCING MARKET SIZE, BY SANGER SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL DNA SEQUENCING MARKET SIZE, BY SANGER SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL DNA SEQUENCING MARKET SIZE, BY SANGER SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL DNA SEQUENCING MARKET SIZE, BY SANGER SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL DNA SEQUENCING MARKET SIZE, BY THIRD-GENERATION SEQUENCING (TGS), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL DNA SEQUENCING MARKET SIZE, BY THIRD-GENERATION SEQUENCING (TGS), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL DNA SEQUENCING MARKET SIZE, BY THIRD-GENERATION SEQUENCING (TGS), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL DNA SEQUENCING MARKET SIZE, BY THIRD-GENERATION SEQUENCING (TGS), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL DNA SEQUENCING MARKET SIZE, BY THIRD-GENERATION SEQUENCING (TGS), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL DNA SEQUENCING MARKET SIZE, BY THIRD-GENERATION SEQUENCING (TGS), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL DNA SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL DNA SEQUENCING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL DNA SEQUENCING MARKET SIZE, BY AGRICULTURAL GENOMICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL DNA SEQUENCING MARKET SIZE, BY AGRICULTURAL GENOMICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL DNA SEQUENCING MARKET SIZE, BY AGRICULTURAL GENOMICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL DNA SEQUENCING MARKET SIZE, BY AGRICULTURAL GENOMICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL DNA SEQUENCING MARKET SIZE, BY AGRICULTURAL GENOMICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL DNA SEQUENCING MARKET SIZE, BY AGRICULTURAL GENOMICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL DNA SEQUENCING MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL DNA SEQUENCING MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL DNA SEQUENCING MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL DNA SEQUENCING MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL DNA SEQUENCING MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL DNA SEQUENCING MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL DNA SEQUENCING MARKET SIZE, BY GENETIC DISEASE RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL DNA SEQUENCING MARKET SIZE, BY GENETIC DISEASE RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL DNA SEQUENCING MARKET SIZE, BY GENETIC DISEASE RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL DNA SEQUENCING MARKET SIZE, BY GENETIC DISEASE RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL DNA SEQUENCING MARKET SIZE, BY GENETIC DISEASE RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL DNA SEQUENCING MARKET SIZE, BY GENETIC DISEASE RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL DNA SEQUENCING MARKET SIZE, BY MICROBIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL DNA SEQUENCING MARKET SIZE, BY MICROBIOLOGY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL DNA SEQUENCING MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL DNA SEQUENCING MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL DNA SEQUENCING MARKET SIZE, BY MICROBIOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL DNA SEQUENCING MARKET SIZE, BY MICROBIOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL DNA SEQUENCING MARKET SIZE, BY MICROBIOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL DNA SEQUENCING MARKET SIZE, BY MICROBIOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL DNA SEQUENCING MARKET SIZE, BY MICROBIOME ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL DNA SEQUENCING MARKET SIZE, BY MICROBIOME ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL DNA SEQUENCING MARKET SIZE, BY MICROBIOME ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL DNA SEQUENCING MARKET SIZE, BY MICROBIOME ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL DNA SEQUENCING MARKET SIZE, BY MICROBIOME ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL DNA SEQUENCING MARKET SIZE, BY MICROBIOME ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL DNA SEQUENCING MARKET SIZE, BY PATHOGEN DETECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL DNA SEQUENCING MARKET SIZE, BY PATHOGEN DETECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL DNA SEQUENCING MARKET SIZE, BY PATHOGEN DETECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL DNA SEQUENCING MARKET SIZE, BY PATHOGEN DETECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL DNA SEQUENCING MARKET SIZE, BY PATHOGEN DETECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL DNA SEQUENCING MARKET SIZE, BY PATHOGEN DETECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL DNA SEQUENCING MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL DNA SEQUENCING MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL DNA SEQUENCING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL DNA SEQUENCING MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL DNA SEQUENCING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL DNA SEQUENCING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL DNA SEQUENCING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL DNA SEQUENCING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL DNA SEQUENCING MARKET SIZE, BY CANCER GENOTYPING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL DNA SEQUENCING MARKET SIZE, BY CANCER GENOTYPING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL DNA SEQUENCING MARKET SIZE, BY CANCER GENOTYPING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL DNA SEQUENCING MARKET SIZE, BY CANCER GENOTYPING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL DNA SEQUENCING MARKET SIZE, BY CANCER GENOTYPING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL DNA SEQUENCING MARKET SIZE, BY CANCER GENOTYPING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL DNA SEQUENCING MARKET SIZE, BY TUMOR PROFILING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL DNA SEQUENCING MARKET SIZE, BY TUMOR PROFILING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL DNA SEQUENCING MARKET SIZE, BY TUMOR PROFILING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL DNA SEQUENCING MARKET SIZE, BY TUMOR PROFILING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL DNA SEQUENCING MARKET SIZE, BY TUMOR PROFILING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL DNA SEQUENCING MARKET SIZE, BY TUMOR PROFILING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL DNA SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL DNA SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL DNA SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL DNA SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL DNA SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL DNA SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL DNA SEQUENCING MARKET SIZE, BY PRENATAL TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL DNA SEQUENCING MARKET SIZE, BY PRENATAL TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL DNA SEQUENCING MARKET SIZE, BY PRENATAL TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL DNA SEQUENCING MARKET SIZE, BY PRENATAL TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL DNA SEQUENCING MARKET SIZE, BY PRENATAL TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL DNA SEQUENCING MARKET SIZE, BY PRENATAL TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL DNA SEQUENCING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL DNA SEQUENCING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL DNA SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL DNA SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL DNA SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL DNA SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL DNA SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL DNA SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL DNA SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL DNA SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL DNA SEQUENCING MARKET SIZE, BY GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL DNA SEQUENCING MARKET SIZE, BY GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL DNA SEQUENCING MARKET SIZE, BY GOVERNMENT RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL DNA SEQUENCING MARKET SIZE, BY GOVERNMENT RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL DNA SEQUENCING MARKET SIZE, BY GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL DNA SEQUENCING MARKET SIZE, BY GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL DNA SEQUENCING MARKET SIZE, BY UNIVERSITY LABS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL DNA SEQUENCING MARKET SIZE, BY UNIVERSITY LABS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL DNA SEQUENCING MARKET SIZE, BY UNIVERSITY LABS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL DNA SEQUENCING MARKET SIZE, BY UNIVERSITY LABS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL DNA SEQUENCING MARKET SIZE, BY UNIVERSITY LABS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL DNA SEQUENCING MARKET SIZE, BY UNIVERSITY LABS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL DNA SEQUENCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL DNA SEQUENCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL DNA SEQUENCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL DNA SEQUENCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL DNA SEQUENCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL DNA SEQUENCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL DNA SEQUENCING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL DNA SEQUENCING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL DNA SEQUENCING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL DNA SEQUENCING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL DNA SEQUENCING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL DNA SEQUENCING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL DNA SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL DNA SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL DNA SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL DNA SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL DNA SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL DNA SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL DNA SEQUENCING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL DNA SEQUENCING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS DNA SEQUENCING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS DNA SEQUENCING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS DNA SEQUENCING MARKET SIZE, BY OFFERINGS, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS DNA SEQUENCING MARKET SIZE, BY OFFERINGS, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS DNA SEQUENCING MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS DNA SEQUENCING MARKET SIZE, BY CONSUMABLES & REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS DNA SEQUENCING MARKET SIZE, BY INSTRUMENTS & PLATFORMS, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS DNA SEQUENCING MARKET SIZE, BY INSTRUMENTS & PLATFORMS, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS DNA SEQUENCING MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS DNA SEQUENCING MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS DNA SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS DNA SEQUENCING MARKET SIZE, BY WORKFLOW, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS DNA SEQUENCING MARKET SIZE, BY DATA ANALYSIS, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS DNA SEQUENCING MARKET SIZE, BY DATA ANALYSIS, 2025-2032 (USD MILLION)
  • TABLE 287. AMERICAS DNA SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, 2018-2024 (USD MILLION)
  • TABLE 288. AMERICAS DNA SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, 2025-2032 (USD MILLION)
  • TABLE 289. AMERICAS DNA SEQUENCING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. AMERICAS DNA SEQUENCING MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. AMERICAS DNA SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 292. AMERICAS DNA SEQUENCING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 293. AMERICAS DNA SEQUENCING MARKET SIZE, BY MICROBIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 294. AMERICAS DNA SEQUENCING MARKET SIZE, BY MICROBIOLOGY, 2025-2032 (USD MILLION)
  • TABLE 295. AMERICAS DNA SEQUENCING MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 296. AMERICAS DNA SEQUENCING MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 297. AMERICAS DNA SEQUENCING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 298. AMERICAS DNA SEQUENCING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 299. AMERICAS DNA SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, 2018-2024 (USD MILLION)
  • TABLE 300. AMERICAS DNA SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, 2025-2032 (USD MILLION)
  • TABLE 301. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 302. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 303. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY OFFERINGS, 2018-2024 (USD MILLION)
  • TABLE 304. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY OFFERINGS, 2025-2032 (USD MILLION)
  • TABLE 305. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 306. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY CONSUMABLES & REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 307. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY INSTRUMENTS & PLATFORMS, 2018-2024 (USD MILLION)
  • TABLE 308. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY INSTRUMENTS & PLATFORMS, 2025-2032 (USD MILLION)
  • TABLE 309. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 310. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 311. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2024 (USD MILLION)
  • TABLE 312. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY WORKFLOW, 2025-2032 (USD MILLION)
  • TABLE 313. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY DATA ANALYSIS, 2018-2024 (USD MILLION)
  • TABLE 314. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY DATA ANALYSIS, 2025-2032 (USD MILLION)
  • TABLE 315. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, 2018-2024 (USD MILLION)
  • TABLE 316. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, 2025-2032 (USD MILLION)
  • TABLE 317. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 318. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 319. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 320. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 321. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY MICROBIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 322. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY MICROBIOLOGY, 2025-2032 (USD MILLION)
  • TABLE 323. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 324. NO